<DOC>
	<DOCNO>NCT01474278</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind study evaluate exploratory biomarkers safety tolerability single dose RO5028442 adult male high-functioning autistic patient . In cross-over design , patient randomize receive either single dose RO5028442 match placebo washout period 7-14 day . Anticipated time study approximately 9 week .</brief_summary>
	<brief_title>A Study RO5028442 Adult Male High-Functioning Autistic Patients</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<criteria>Patients diagnosis Autistic Disorder define DSMIV , confirm team support Autistic Diagnostic Observation Schedule ( ADOS ) Male adult , 18 45 year age IQ &gt; 70 ( Wechsler Adult Intelligence ScaleFull scale ) Body mass index ( BMI ) 18 35 kg/m2 inclusive Aberrant Behavior Checklist ( ABC ) Irritability subscale score &lt; /= 13 Positive urine test drug abuse Alcohol and/or substance abuse/dependence last 12 month Positive hepatitis B , hepatitis C HIV infection Clinically relevant cardiovascular , renal , hepatic hematologic disease disorder Active inflammatory pulmonary disease History epilepsy/seizure disorder ( except simple febrile seizure ) Initiation new major change psychosocial intervention within 4 week prior randomization Treatment investigational agent within 90 day prior screen History hypersensitivity allergic reaction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>